AMG 710

AMG 710 (also known as AM-710) is an orally bioavailable small molecule inhibitor developed by Amgen for the treatment of advanced solid tumors. It functions as a dual antagonist of the vascular endothelial growth factor receptor (VEGFR) and the Tie2 (TEK) tyrosine kinase. By targeting these two distinct pathways involved in tumor angiogenesis, AMG 710 was designed to inhibit the formation of new blood vessels more effectively than agents targeting VEGFR alone. Tie2 is primarily expressed on endothelial cells and plays a crucial role in vessel maturation and stability, while VEGFR signaling is the primary driver of endothelial cell proliferation and migration. Despite its rational design for potent anti-angiogenic activity, clinical development of AMG 710 was discontinued following Phase 1 trials.